Originally annotated as the initiator of fatty acid synthesis (FAS), b-ketoacyl-acyl carrier protein synthase III (KAS III) is a unique component of the bacterial FAS system. Novel variants of KAS III have been identified that promote the de novo use of additional extracellular fatty acids by FAS. These KAS III variants prefer longer acyl-groups, notably octanoylCoA. Acinetobacter baumannii, a clinically important nosocomial pathogen, contains such a multifunctional KAS III (AbKAS III). To characterize the structural basis of its substrate specificity, we determined the crystal structures of AbKAS III in the presence of different substrates. The acyl-group binding cavity of AbKAS III and co-crystal structure of AbKAS III and octanoyl-CoA confirmed that the cavity can accommodate acyl groups with longer alkyl chains. Interestingly, Cys264 formed a disulfide bond with residual CoA used in the crystallization, which distorted helices at the putative interface with acyl-carrier proteins. The crystal structure of KAS III in the alternate conformation can also be utilized for designing novel antibiotics.
Introduction
Fatty acid synthesis (FAS) provides building blocks for lipid bilayers in biological membranes and is essential for the viability of all bacteria (Rock and Cronan, 1996) . In contrast to fungal or mammalian cytosolic fatty acid synthase I (FAS I) systems, which use complexes of multi-domain enzymes, bacterial FAS II systems utilize individual proteins participating stepwise in fatty acid elongation (White et al., 2005) . FAS II has an advantage in that condensing intermediates can be diverted to secondary metabolites, such as quorum-sensing autoinducers and lipopolysaccharide (LPS) (Yao and Rock, 2015) . In Escherichia coli, b-ketoacyl-acyl carrier protein synthase III (EcKAS III) initiates fatty acid elongation by condensing 2-carbon units from acyl-CoA and malonyl acyl-carrier protein (ACP) (Lai and Cronan, 2003) . After reduction and dehydration of the carbonyl group, further elongation of acyl-ACP occurs via KAS I or KAS II (FabB or FabF in E. coli respectively), depending on the substrate (Rock and Cronan, 1996) . In contrast to KAS III, KAS I and KAS II can accept alkyl groups from alkyl-ACP rather than alkyl-CoAs. By priming ACPs for FAS, KAS III can control the overall output of fatty acids and should be tightly regulated. In this regard, KAS III deletion in E. coli causes severe reduction of cell size and compromises the growth rate (Yao et al., 2012) .
These condensing enzymes are attractive targets for antibiotic discovery. Thiolactomycin and cerulenin, which are natural inhibitors of KAS I and KAS II, have been isolated from soil bacteria and thoroughly investigated (D'Agnolo et al., 1973; Oishi et al., 1982; Moche et al., 1999; Price et al., 2001) . More recently, platencin, an inhibitor of both KAS II and KAS III, was also identified (Wang et al., 2007) . High-throughput screening combined with rational drug design and synthesis also yielded lead compounds functioning as KAS III inhibitors (Daines et al., 2003; Li et al., 2014; Song et al., 2014) . Concerns regarding FAS II inhibitors have been raised because human serum is a rich source of fatty acids in vivo, and FAS II genes could become dispensable for gram-positive pathogens (Brinster et al., 2009) . However, FAS II is essential for Staphylococcus aureus infection (Balemans et al., 2010) , and the validity of FAS II targeting should be considered based on the specific pathogens in question.
In Pseudomonas aeruginosa, FabY (a distant homologue of KAS III) initiates FAS more efficiently than the other 3 orthologues of KAS III present in its genome (Yuan et al., 2012b) . Furthermore, PA3286, one of the 4 KAS III orthologues in P. aeruginosa, prefers octanoylCoA to acetyl-CoA and utilizes extracellular fatty acids for de novo FAS (Yuan et al., 2012a) . It is noteworthy that this incorporation of fatty acids in the form of octanoyl-CoA links fatty acid b-oxidation with FAS (Yuan et al., 2012a) and channels decanoyl-ACP into secondary metabolites such as rhamnolipids, LPS, acylhomoserine lactones and alkyl-quinolones, most of which are important virulence factors (Zhang and Rock, 2012) . As KAS III proteins are eligible targets for antibacterial drugs (Parsons and Rock, 2011) , the inhibition of PA3286 and its homologues may be an interesting subject of antibiotic development programs.
Acinetobacter baumannii is an important nosocomial pathogen that has shown an alarming increase in multidrug resistance (MDR) A. baumannii strains have become a major challenge in antibacterial drug development. Some members of the Acinetobacter genus are highly competent for natural transformation and thus readily acquire foreign DNA to attain antibiotic resistance (Young et al., 2005) . The A. baumannii genome contains highly mosaic pathogenicity islands, which mainly encode resistance marker genes and antiseptic resistance genes (Fournier et al., 2006) . As a result, A. baumannii can acquire resistance in a short period time, and fundamentally new lines of antibiotics need to be developed. In previous studies, we focused on identifying antimicrobial reagents targeting the KAS III gene of various pathogens Lee et al., 2009; Lee et al., 2011; Lee et al., 2012) and searched for AbKAS III inhibitors to address this issue (Lee et al., 2017) .
Despite the increasing interest in multi-drug resistant A. baumannii, its FAS mechanism has been poorly characterized. Based on BLAST searches, we found that A. baumannii has only one KAS III orthologue (AbKAS III) in its genome, which is highly homologous to PA3286 (amino acid identity 58%, 215 out of 368 residues) (Fig.  1A) . However, A. baumannii has no FabY-like protein for FAS initiation and it appears that AbKAS III accepts acetyl-CoAs of various lengths and channels them into FAS or other secondary metabolite pathways in addition to FAS initiation.
The primary structure of AbKAS III shares interesting features with PA3286 when compared to EcKAS III. First, 2 insertions ( 30 residues total) are inserted in the sequence. Second, key residues involved in substrate binding are different from EcKAS III; among the residues involved with substrate recognition, Phe56 sits in the position of EcKAS III's Trp32 for p-stacking interactions with CoA's purine rings. To understand the structure-function relationship of AbKAS III with these distinctive features, we determined its crystal structure and assayed the activities of its mutants.
Results

Overall structure of AbKASIII
Crystals of AbKAS III belong to the C2 monoclinic space group and contain 2 molecules of AbKAS III in the asymmetric unit. The structure of AbKAS III was solved using an unpublished structure of a KAS III protein from Rhodopseudomonas palustris as a model (PDB ID 3LED). The model protein displays 56% amino acid identity with AbKAS III and shares the above-mentioned features of PA3286 with AbKAS III. Similar to other KAS III proteins, AbKAS III forms a homodimer, related by a twofold non-crystallographic symmetry, to fill the asymmetric unit (Fig. 1B) . Both chains share almost identical structures with an r.m.s.d. of 0.16 Å . The overall fold of AbKAS III displays typical KAS III structures, which include 2 thiolase-fold domains merged with additional insertions for substrate binding (Haapalainen et al., 2006; Gajiwala et al., 2009) . Arguably the most prominent feature of the structure is the helical structure of the N-terminal CoA-binding region (Fig. 1B) . The Nterminal domain differs from those of KAS I or KAS II, which have marginal affinity to acyl-CoA. The inserted a-helix (Ser26-Arg50) is separated from the active site and extends along the twofold of the dimer (yellow helix in Fig 1B) . A similar N-terminal insertion was observed in the KS domain of germicidin synthase from Streptomyces coelicolor (Chemler et al., 2012) . In contrast to the dimeric interaction of germicidin synthase, the insertion is not present at the dimeric interface. Residues exposed to the solvent showed high B-factors and relatively poorly defined electron densities. The inserted helix features a kink at Asn37 (Fig. 1C) . The side chain of Asn37 forms a hydrogen bond with the main chain carbonyl group of Tyr33 and stacks with its aromatic ring. Tyr33-Tyr29 p-p interaction and Leu80 from the second inserted sequence supported by Asp76-Arg83 and Arg79-Asp244 ion pairs reinforce the base of this helical extension (Fig. 1C) .
Crystal structures of KAS III have revealed a CysHis-Asn triad in the active site (Qiu et al., 1999) rather than the Cys-His-Hs triad found in KAS I and KAS II (Huang et al., 1998; Olsen et al., 1999) . The structure of AbKAS III revealed that Cys155, His291 and Asn324 are present in the active site and appear to form a triad, as found in other KAS III proteins (Fig. 1B) (Gajiwala et al., 2009) . The His and Asn residues were found to be in a similar orientation to that found in EcKAS III (Zhang et al., 2006) . Previous data showed that Phe304 is near the catalytic triad in EcKAS III (Phe352 in AbKAS III), but could rotate by approximately 1508 depending on substrate binding. The stacking interaction between Phe and His residues in the absence of substrate appears to protect the active site Cys residue against the solvent (Qiu et al., 2005) . However, in the AbKAS III structure, Phe352 is in the open state with or without bound substrates (Fig. 1B) .
Previous data revealed that positively charged residues (Lys214, Arg249 and Lys 256) are involved in protein-protein interactions between EcKAS IIIs and ACPs (Zhang et al., 2001) . In AbKAS III, positively charged residues are conserved in the putative ACP-binding site (Fig. 2) . In AbKAS III structures, the conserved Lys261 and Lys303 superimpose well with Lys214 and Lys256 in EcKAS III respectively. Interestingly, Arg249 of EcKAS III, which was also implicated in ACP binding, corresponds to Asn296 in AbKAS III (Fig. 2) . In contrast, the conserved residue Arg257 of AbKAS III replaces Asn210 of EcKAS III. When we superimposed the ligand-bound structures, these Arg residues interacted with the diphosphate moiety of CoA rather than ACP (Fig. 2) .
Substrate binding of AbKAS III
To understand the structure-function relationship of substrate specificity, we crystallized the AbKAS III C155A mutant with octanoyl-CoA. The crystals form in the same crystallization condition as the apo crystals but in a distinct shape and in the space group of P2 1 2 1 2 1 (Supporting Information Table S1 ). In the structure at the resolution of 2.0 Å with an R-factor of 0.212 (free-R 5 0.259), we identified a clear electron density for the 3'-phoshoadenosine moiety of the substrates in only one of the two protomers in the asymmetric unit. In the structure of EcKAS III in complex with CoA, Trp32 and PA3286, KAS III orthologue of P. aeruginosa; Rap0194, Ralstonia solanacearum (Mao et al., 2015) , and EcKAS III, KAS III of E.coli. Two main insertions in AbKAS III are highlighted in yellow. Tyr131 and His187 residues, putative cavity opening residues, are highlighted in cyan. The cysteine nucleophile in the active site is marked with a star. CoA binding Trp (AbKAS III) or Phe (EcKAS III) are marked with a triangle. B. Overall structure of AbKAS III depicted in a ribbon model. The inserted sequences are colored in yellow. The location of active site pocket is indicated by a dotted box. Active site residues of the amino acid triad and gating Phe352 are displayed in the inset figure. C. Asn37 and other residues important for the conformation of inserted helix displayed in sticks and labeled.
Crystal structure of Acinetobacter baumannii KAS III 569 Molecular Microbiology, 108, [567] [568] [569] [570] [571] [572] [573] [574] [575] [576] [577] Arg151 interact with the adenosine ring by hydrophobic interactions (Qiu et al., 2001) . In the structure of AbKAS III, Phe56 (which corresponds to Trp32 in EcKAS III) and Arg193 participate in this p-stacking interaction (Fig. 3A) . Phe56 is conserved among PA3286-family proteins, and we suspected Phe56 to be important for its unique substrate specificity (Fig 1A) . When we mutated Phe56 of AbKAS III to Trp, a drastic change in reactivity towards octanoyl-CoA was not detected even though the band of F56W variant was reduced approximately by 40% (Fig. 3B) . We also prepared the EcKAS III W32F mutant to examine whether this variant can accept longer acyl-CoAs that serve as AbKAS III substrates. The W32F mutation did not affect the substrate specificity of EcKAS III and even decreased by 30% as measured in the residual band (Fig. 3C) . Combined, Phe56 of AbKAS III at the position by EcKAS III appear to have been optimized for facile accommodation of octanoyl-CoA.
When we traced the remaining electron density of the substrate, we found that octanoyl-CoA was positioned towards Cys264, not Cys155. It appears that a degraded form of octanoyl-CoA or a residual CoA contaminant formed a covalent bond with Cys264. (Fig.  3A) . The bifurcation is remiscent of the structure of OleA, a thiolase from long-chain olefin biosynthesis cluster (Goblirsch et al., 2016) . To prevent this nonproductive complex formation, we mutated Cys264 to Ala and crystallized the variant in the presence of octanoyl-CoA. Analysis of the 2.3-Å diffraction data (Rfactor 0.167, free-R 5 0.221) revealed significant electron density for octanoyl-CoA (Supporting Information  Fig. S1 ). As observed in the structure of CoA covalent complex, the electron density of octanoyl-CoA was found in one protomer of the dimer in the asymmetric unit in another space group of C222 1 . This time, the acyl moiety was leaning towards the active site pocket. We compared both conformations of Phe260 and Met297 to study active site expansion and the emergence of a new binding pocket (Fig. 3A) .
The electron density of each bound substrate is well defined at the 3'-phosphoadenosine and diphosphate moieties (Supporting Information Fig. S1 )The pantothenate group is less defined for C8-CoA due to disorder (Supporting Information Fig. S1B ). However, the thioester carbonyl forms hydrogen bonds with His291 and Asn324, two active site residues (Supporting Information Fig. S1C ). This specific interaction of C8-CoA's thioester carbonyl group with the active site triad conforms to the reaction mechanism of KAS III, which requires a thioester intermediate to the active site cysteine.
Substrate specificity of AbKAS III
We superimposed the AbKAS III C155A/C264A doublemutant structure bound to octanoyl-CoA with the EcKAS III structure to understand the structure-function relationship (Fig 4A) . The acyl group-binding pocket of AbKAS III is defined by residues Ser125, Tyr131, Thr184, His187, Leu188, Phe199, Phe252 and Ser326 (Fig. 4A, Supporting Information Fig. S3 ). Among these residues,Tyr131, His187, Leu188, Phe199 and Phe252 are conserved among PA3286-like KAS IIIs. Phe199 is one of the most conserved residues and important for forming the active site of all KAS IIIs. Tyr131 and His187 side chains form a hydrogen bond, resulting in opening of the cavity, which is blocked by Phe87 in EcKAS III (Fig. 4A ). In the primary structure, Tyr131 and His187 residues are conserved among PA3286-like KAS IIIs (Fig. 1) , underlining the important of this hydrogen bond in opening the cavity. When we performed a BLAST search of PA3286-like KAS IIIs, we found that all members of this family have a Tyr residue at this position (data not shown), whereas few members have a Gln at the position of His187. As a result, The Tyr-His/ Gln association is a feature of PA3286 family KAS IIIs and relevant for the expansion of the cavity for binding of longer alkyl-CoA substrates. Phe252 replaces Leu205 in EcKAS III and functions by guiding the alkyl chain into the cavity. Furthermore, Thr184 recedes further at the end of the cavity when compared to Leu 141. However, in EcKAS III, Phe87 and Leu141 (corresponding to Tyr131 and Thr184 in AbKAS III respectively) blocked Red arrows indicate altered migration of reaction products. The minor protein bands above ACP belong to apo-ACP, which was copurified with holo-ACP from AcpS co-expression system. the cavity. As a result, EcKAS III can only accept acetyl-CoA.
To determine whether AbKAS III is indeed an effective acceptor of octanoyl-CoA similar to PA3286, the activity of AbKAS III was assessed by conformation-sensitive electrophoresis (Rock and Cronan, 1981) . Our reaction condition was set up such that most substrate ACPs were turned over to the products (Supporting Information Fig. S4 ). For AbKAS III, the reaction almost finished even with a tenth of the amount of the enzyme and it appears that AbKAS III was more efficient than EcKAS III. Initially, we removed the first inserted domain of AbKAS III to examine its functional relevance to activity. After the removal of 20 amino acids in the first insertion, which corresponds to the protruding helix, the expression level of DAbKAS III decreased significantly because most AbKAS III was found in the insoluble fraction of the lysate (data not shown). DAbKAS III was purified using the same scheme as the wild-type protein. The CD spectrum of DAbKAS III showed a slight deviation from the wild-type protein due to the lack of this short helix (data now shown). However, DAbKAS III was as active as the wild-type protein in terms of octanoyl-CoA incorporation; thus, it appears that this inserted sequence is not essential for activity (Fig. 4B) . The results confirmed that AbKAS III is active towards octanoyl-CoA. In contrast, EcKAS III can accept substrates as large as butyryl-CoA, but is not reactive towards hexanoyl-CoA or octanoyl-CoA.
Discussion
Given the persevering threat of multi-drug resistant A. baumannii, understanding the fundamental metabolism relevant to virulence is of great interest. As the novel KAS III family can contribute to shuttling external fatty acids into de novo FAS, AbKAS III may be important for pathogenicity in vivo. However, little is known about the FAS pathways of A. baumannii, and detailed structures of FAS-related proteins from A. baumannii are still lacking except for the unpublished structure of FabI (PDB ID: 4ZJU). To our knowledge, the AbKAS III structures reported here represent the first report of A. baumannii FAS II protein structures. In the genome sequence of A. baumannii, distinct fatty acid biosynthesis gene clusters can be identified. In A. baumannii, ACICU, KAS I, KAS II, FabG, ACP and AcpS form a gene cluster (Supporting Information Fig. S5A) . Intriguingly, these genes are part of a larger cluster of genes involved in modifying fatty acids. Furthermore, the cluster contains acyl-CoA synthetase, which assembles acyl-CoA from free fatty acids. As AbKAS III readily accepts long-chain acylCoAs, the FAS gene cluster of A. baumannii appears to have adapted to channeling fatty acids into de novo FAS.
Together with Pseudomonas and other PA3286-like KAS III-containing bacteria, Acinetobacter forms a subgroup of gammaproteobacteria. The N-terminal insertion sequences are conserved along with Tyr131 and His187. The insertion sequence is not necessary for the condensation reaction in vitro and it is likely the inserted structure is required for protein-protein interaction with a yet-to-be-identified protein or subcellular localization.
Although the KAS III gene forms a cluster with FAS genes, blocks of genes are transcribed independently in E. coli (Zhang and Cronan, 1996) . In the genomic context of AbKAS III, we found no correlation of the gene with its genomic neighbors (Supporting Information Fig.  S5B) . A similar tendency was found for orthologues in closely related species such as Pseudomonas (data not shown). In the A. baumannii ACICU genome, the AbKAS III gene is located near a benzoate permease and oxidative degradation-related genes. Chalcone synthase-type thiolase superfamily proteins are involved in various alternate pathways other than FAS (Haapalainen et al., 2006 , Ferrer et al., 1999 , and no exception is found for FabH proteins. For example, an acetoacetylCoA synthase similar to FabH, implicated in the mevalonate pathway, was found in Streptomyces sp. CL190 (Okamura et al., 2010) . Orf3 of P. syringae, another FabH orthologue, was found amid genes mediating flagellin glycosylation (Taguchi et al., 2006) . PqsD participates in 2,4-dihydroxyquinoline biosynthesis for quinolone signaling in P. aeruginosa (Zhang et al., 2008; Bera et al., 2009 ) and similar function as quorum signaling in A. baumannii is possible.The presence of hydrophilic residues such as His in this cavity implies that AbKAS III can also accept unknown substrates with hydrophilic functional groups. Considering the genomic context and functional versatility, it is tempting to speculate that it has additional functions in unknown catabolic or synthetic pathways.
Disrupting AbKAS III activity is one of our goals for gaining control over A. baumannii infection. The substrate-binding site is defined by CoA-binding cavities as noted in previously solved KAS III structures (Qiu et al., 1999; Davies et al., 2000) . The malonyl groupbinding pocket has been a site of particular interest as natural inhibitors of KAS I and KAS II target the corresponding position. In the EcKAS III-inhibitor complex structure, the 1,5-dichlorobenzene group of compound 5 also fits into this pocket (Fig. 5A) (Daines et al., 2003) . When the EcKAS III-compound 5 complex structure is superposed with the apo structure of AbKAS III, steric inhibition by Met297 in AbKAS III inhibits the binding of compound 5 (Fig. 5A) . However, the AbKAS III-CoA complex displays an alternative rotameric conformation with Met297 and opens up additional space for binding (Fig. 5B) The void can be filled by modifying the 1,5-dichlorobenzene group moiety of compound 5. We expect that the expanded binding site in this Crystal structure of Acinetobacter baumannii KAS III 573 conformation can be utilized for designing more efficient and specific inhibitors of KAS III.
Our structures and functional annotation of AbKAS III confirm the unique features of novel KAS IIIs such as PA3286 from P. aeruginosa. As A. baumannii and P. aeruginosa belong to g-proteobacteria and problematic nosocomial pathogens, it will be of interest to determine whether the functional similarities of FAS enzymes are shared in terms of their genomic context. In P. aeruginosa, FabY is a more effective initiator of FAS. However, no orthologue of FabY is found in the genome of A. baumannii ACICU (data not shown). The P. aeruginosa genome contains 4 KAS III orthologues, whereas only one is found in the A. baumannii genome. Our structure and functional data suggest that AbKAS III may be a versatile condensing enzyme encompassing various substrates. Thiolase family proteins from polyketide synthases have also been actively studied for bioengineering and antibiotics development (Gokulan et al., 2013; Mori et al., 2015; Drees et al., 2016) . The structural insight from AbKAS III structures will help in understanding growing number of condensing enzymes in general.
Experimental procedures
Purification and crystallization of AbKASIII
AbKASIII was amplified from the genomic DNA of A. baumannii ACICU by PCR and cloned into pET15b to include a 6-His tag and a thrombin cleavage site at the N-terminus (Bouvet and Grimont, 1986) . AbKAS III was expressed in E. coli BL21 (DE3) cells with 0.2 mM isopropyl-b-Dthiogalactopyranoside (IPTG) and induced at 258C for 20 h. Cells were harvested by centrifugation and stored at 2208C until use. For purification, cells were resuspended in lysis buffer (20 mM Tris HCl [pH 8] and 100 mM NaCl) and sonicated for 10 min on ice. Each lysate was cleared by centrifugation and filtered through a 0.22-lm cellulose filter before purification by chromatography. A 5-ml Chelating Sepharose HP column (GE Healthcare) was used to bind AbKAS III and then washed with lysis buffer containing 25 mM imidazole. AbKAS III was eluted in a 30-ml gradient of 25-500 mM imidazole. Imidazole was removed by iterative concentration with an Amicon filter (Merck) and dilution.
AbKAS III was crystallized using PEG3350 as a precipitant and Tris HCl buffer (pH 7-8) and 0.1 M calcium acetate, and incubated at 208C. Crystals appeared overnight and reached their maximum size in 2 days. For complex crystallization, AbKAS III and variants were mixed with substrates on ice for 1 h and crystallized under the same conditions. To prevent crystal deterioration, crystals were promptly harvested in a cryoprotectant containing 20% ethylene glycol and stored in liquid nitrogen until data collection. For crystallization with CoA or C8-CoA with mutants, proteins were incubated with 10 mM CoAs for an hour on ice and set up with the same crystallization buffer as the native protein.
Structure determination and refinement X-ray diffraction data were collected at Pohang Accelerator Laboratory beamline 7A. Crystals were kept at 21738C during data collection to prevent radiation damage. Diffraction images were integrated and scaled using the HKL2000 program suite (Otwinowski and Minor, 1997) . The structure of AbKAS III was determined by molecular replacement using the coordinates of R. palutris KAS III (RpKAS III; PDB ID, 3LED) as a search model. An initial structure was built using the PHENIX program (Adams et al., 2010) and modified using the WinCoot program (Emsley and Cowtan, 2004) .
Cloning and purification of holo EcACP and EcFabD
For expression of EcACP in the holo form, the open reading frame (ORF) of EcACP was cloned into the NcoI/SacI sites of the pETDuet-1 vector, with EcAcpS in the second multiple-cloning site (NdeI/SalI). The co-expression vector was transformed into E. coli BL21(DE3) cells and incubated at 378C for 2 h with induction by 0.4 mM IPTG. Cells were harvested and stored at 2208C until use. EcACP was purified using a 5-ml HiTrap Q-Sepharose FF column (GE Healthcare) with a gradient of 0-0.6 M NaCl. EcACPcontaining fractions were concentrated and further purified with a Superdex 200 column (GE Healthcare) in 2 mM DTT, 20 mM Tris (pH 8), and 100 mM NaCl. Holo EcACP was concentrated and stored at 2808C until use. The ORF of EcFabD was cloned into the pET28a vector between the NdeI and BamHI restriction sites. EcFabD was expressed in E. coli BL21 (DE3) cells by induction at 258C for 16 h. EcFabD purification was performed with the same protocol that was used AbKAS III. Concentrated EcFabD was stored at 2808C until use. EcKAS III was prepared as previously described (Lee et al., 2011) .
Preparation of mutants
nPfu DNA polymerase (Enzynomics) was used to generate point mutations of AbKAS III. To generate the loop-deletion mutant, residues 28-51 were removed by PCR and Leu26 was mutated to Val to yield DAbKAS III. All variants of AbKAS III were expressed and purified using the same purification protocol as described for wild-type AbKAS III.
Activity assay
The activity of AbKAS III was measured by conformationsensitive native-PAGE (Rock and Cronan, 1981) . To enhance separation, 10%-16% gradient native gels containing 2.5 M urea was used and run in Tricine buffer for better band resolution (Schagger, 2006) . The overall scheme of sequential reactions was performed as in situ FabD incorporation of malonyl-CoA into EcACP and subsequent condensation by AbKAS III ensued in the same reaction mix. For better separation of ACP products, E. coli ACP (EcACP) was used rather than AbACP, as the electrophoretic migration of AbACP was not sensitive enough for product separation (data not shown). In detail, EcFabD (0.17 mM) and EcACP (0.75 mM) were mixed with 0.9 mM mal-CoA and incubated for 10 min at room temperature to produce malonyl-EcACP. Subsequently, KAS IIIs (40 lM) and acyl-CoAs (4 mM) were added and the mixture was further incubated for 10 min. Each (10 ll) reactant was loaded onto a native gel (100 3 80 3 0.75 mm) and separated. The gel was stained with R-250 Coomassie Blue for visualization. Gel images were obtained using a flatbed scanner. Protein bands integration was performed by ImageJ software (Schneider et al., 2012) .
Accession numbers
The structure factors and atomic coordinates of AbKAS III (Accession number 5X3W), AbKAS III-C155A in complex with CoA (5YO9) and AbKAS III-C155A-C264A in complex with octanoyl-CoA (5YOA) have been deposited in the Protein Data Bank.
